Immunoglobulin Potency Testing via Pneumolysin Hemolysis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved monitoring of the functional integrity and standardization of immunoglobulin compositions derived from a plurality of donors, as existing methods do not effectively assess the biological activity and conformational changes of immunoglobulins during manufacturing, particularly IgG and IgM, which are susceptible to degradation and vary in antibody content due to donor exposure to specific antigens.
Innovation Solution
A method involving contacting the immunoglobulin composition with pneumolysin and mixing it with erythrocytes to determine lysis, which inversely correlates with the composition's potency, allowing for characterization and quality control of immunoglobulin compositions containing IgG, IgM, and IgA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing monitoring methods are used for immunoglobulin compositions, then manufacturing process is simple, but functional integrity and biological activity cannot be effectively assessed
Solution Approach 1:
The patent introduces an intermediary system consisting of pneumolysin toxin and erythrocytes that mediates the assessment of immunoglobulin biological activity. The toxin-erythrocyte-immunoglobulin interaction chain serves as a bridge between the immunoglobulin composition and the measurable lysis endpoint, enabling indirect but reliable potency assessment without requiring complex direct measurement apparatus.
Solution Approach 2:
The patent replaces complex mechanical or instrumental analysis systems with a simple biological assay system. Instead of using sophisticated equipment to measure conformational changes or biological activity, the invention uses a straightforward lysis inhibition assay where erythrocyte lysis is visually or spectrophotometrically measured, substituting mechanical complexity with biological simplicity.
2Adaptability or versatility
If immunoglobulin compositions are derived from multiple donors, then antibody diversity and coverage are improved, but batch-to-batch variability and standardization become problematic
Solution Approach 1:
The patent implements a feedback mechanism where the lysis inhibition assay results from previous batches inform the standardization of subsequent batches. By measuring the actual biological activity (lysis inhibition percentage) of each batch and comparing it to a reference standard, manufacturers can adjust dosing or pooling strategies to achieve consistent potency across batches derived from multiple donors.
Solution Approach 2:
The patent uses parameter changes in the form of reference standards and potency thresholds to standardize multi-donor immunoglobulin compositions. By establishing reference preparations with defined potency and setting acceptance criteria based on lysis inhibition percentages, the invention enables consistent quality control across batches with varying donor compositions.
3Productivity
If IgG and IgM are subjected to manufacturing processes, then immunoglobulin composition is produced, but conformational changes and degradation occur
Solution Approach 1:
The patent applies preliminary action by assessing immunoglobulin integrity at multiple stages during the manufacturing process rather than only at the final product stage. By performing lysis inhibition assays on intermediates and final products, potential conformational changes or degradation can be detected early, allowing process adjustments before full-scale production is compromised.
Solution Approach 2:
The patent uses a simple, inexpensive, and rapidly performable lysis inhibition assay that can be disposed of after each measurement. The assay reagents (pneumolysin, erythrocytes, buffers) are low-cost and the assay itself can be completed quickly, allowing frequent integrity checks during manufacturing without significantly increasing cost or time, thereby maintaining both productivity and reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a reliable assessment of immunoglobulin potency and integrity, ensuring consistent quality and activity, particularly against pathogens like Streptococcus pneumoniae, by measuring erythrocyte lysis, thereby standardizing the composition for effective treatment or prevention of infections.
Implementation Method 1
pneumolysin-mediated lysis of erythrocytes
Implementation Method 2
neutralizing activities against infectious agents such as bacteria, viruses and their toxins
Data Source
AI summary
The present invention relates to the field of immunotherapeutics. It provides a method for characterisation and quality control, in particular for determining the potency of an immunoglobulin composition comprising immunoglobulins derived from a plurality of human donors, the method comprising contacting the immunoglobulin composition with pneumolysin, adding erythrocytes to the immunoglobulin composition and determining lysis of the erythrocytes. The invention also provides a corresponding use of pneumolysin, as well as a kit and composition useful in said method. The method can be used for quality control of immunoglobulin concentrate, e.g., of an IgM-containing immunoglobulin composition comprising IgM, IgA and IgG antibodies, and in a method of preparing an immunoglobulin composition. The immunoglobulin compositions obtainable from said method may be used, e.g., in the treatment of pneumonia, e.g., severe community-acquired pneumonia, which may be caused, e.g., by Streptococcus pneumoniae.